← Back to Search

Radiation Therapy

Adaptive Radiation Therapy for Pancreatic Cancer (ARTIA-Pancreas Trial)

N/A

Recruiting

Led By Lauren Henke, MD

Research Sponsored by Varian, a Siemens Healthineers Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically or cytologically confirmed borderline-resectable (based on NCCN criteria), locally-advanced (based on NCCN criteria), or medically inoperable pancreatic adenocarcinoma

At least 18 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 90 days from start of treatment

Awards & highlights

ARTIA-Pancreas Trial Summary

This trial will test a cancer treatment with less toxicity, to see if it helps improve survival, local control, and quality of life.

Who is the study for?

This trial is for adults with a specific type of pancreatic cancer that's borderline-resectable, locally-advanced, or inoperable. Participants must have had at least two months of chemotherapy and be able to hold their breath as instructed during treatment. Pregnant individuals, those with certain heart conditions, active infections, or other cancers within the last year can't join.Check my eligibility

What is being tested?

The study tests a high-dose radiation therapy called stereotactic adaptive radiotherapy (50Gy in 5 fractions) on patients with pancreatic cancer. It aims to reduce toxicity compared to traditional treatments while assessing survival rates, tumor control, quality of life and the efficiency of the treatment process.See study design

What are the potential side effects?

While aiming for decreased toxicity, potential side effects may include gastrointestinal issues due to radiation exposure such as nausea or diarrhea. The precise side effects will be monitored throughout the trial.

ARTIA-Pancreas Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My pancreatic cancer is advanced but not yet widely spread.

Select...

I am 18 years old or older.

Select...

I can hold my breath for at least 20 seconds once and 10 seconds repeatedly on command.

Select...

My initial treatment plan and imaging will be reviewed by the study's lead doctors.

Select...

I am fully active or can carry out light work.

ARTIA-Pancreas Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 90 days from start of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 90 days from start of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 90 days from start of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acute Grade 3+ treatment related GI toxicities

Secondary outcome measures

Local in-field Control

Long Term Grade 3+ treatment related GI toxicities

Overall Survival

+1 more

ARTIA-Pancreas Trial Design

1Treatment groups

Experimental Treatment

Group I: Daily Adaptive External Beam Radiation TherapyExperimental Treatment1 Intervention

Daily adaptive radiation therapy delivered with Varian Ethos treatment system

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Washington University School of MedicineOTHER

1,935 Previous Clinical Trials

2,299,739 Total Patients Enrolled

Varian, a Siemens Healthineers CompanyLead Sponsor

30 Previous Clinical Trials

7,139 Total Patients Enrolled

Lauren Henke, MDPrincipal InvestigatorCase Western Reserve University

Media Library

Daily Adaptive External Beam Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05764720 — N/A

Pancreatic Cancer Research Study Groups: Daily Adaptive External Beam Radiation Therapy

Pancreatic Cancer Clinical Trial 2023: Daily Adaptive External Beam Radiation Therapy Highlights & Side Effects. Trial Name: NCT05764720 — N/A

Daily Adaptive External Beam Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05764720 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are partaking in this medical experiment?

"Affirmative, per clinicaltrials.gov the current recruitment status for this trial is active. This medical research was initially posted on March 14th 2023 and edited most recently on March 7th 2023. The study requires participation from 134 individuals at 1 site."

Answered by AI

Are there still vacancies for this scientific exploration?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial is seeking volunteers, with the original posting going up on March 14th of 2023 and a recent update occurring on March 7th of 2023. 134 individuals must be sourced from one medical centre for enrolment in this experiment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

2023. "Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05764720.